IQVIA Holdings Inc. $IQV Shares Acquired by Allstate Corp

Allstate Corp raised its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 97.0% in the fourth quarter, Holdings Channel.com reports. The fund owned 12,359 shares of the medical research company’s stock after purchasing an additional 6,085 shares during the period. Allstate Corp’s holdings in IQVIA were worth $2,786,000 at the end of the most recent quarter.

A number of other institutional investors have also made changes to their positions in the stock. Brighton Jones LLC grew its holdings in shares of IQVIA by 244.4% in the fourth quarter. Brighton Jones LLC now owns 3,575 shares of the medical research company’s stock valued at $703,000 after purchasing an additional 2,537 shares in the last quarter. Empowered Funds LLC grew its holdings in shares of IQVIA by 102.1% in the first quarter. Empowered Funds LLC now owns 9,728 shares of the medical research company’s stock valued at $1,715,000 after purchasing an additional 4,915 shares in the last quarter. Sivia Capital Partners LLC acquired a new position in shares of IQVIA in the second quarter valued at approximately $514,000. First Trust Advisors LP grew its holdings in shares of IQVIA by 14.8% in the second quarter. First Trust Advisors LP now owns 92,015 shares of the medical research company’s stock valued at $14,501,000 after purchasing an additional 11,845 shares in the last quarter. Finally, NewEdge Advisors LLC grew its holdings in shares of IQVIA by 5.4% in the second quarter. NewEdge Advisors LLC now owns 22,731 shares of the medical research company’s stock valued at $3,582,000 after purchasing an additional 1,155 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IQV has been the subject of a number of research reports. TD Cowen upgraded shares of IQVIA from a “hold” rating to a “buy” rating and lifted their price objective for the company from $174.00 to $213.00 in a report on Monday, March 9th. Weiss Ratings cut shares of IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a report on Monday, May 4th. Truist Financial dropped their price objective on shares of IQVIA from $290.00 to $245.00 and set a “buy” rating for the company in a report on Thursday, February 19th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, Morgan Stanley set a $225.00 price target on shares of IQVIA in a research note on Thursday, May 7th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and two have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Buy” and an average target price of $225.69.

IQVIA Stock Up 2.5%

Shares of IQVIA stock opened at $165.97 on Thursday. IQVIA Holdings Inc. has a 52-week low of $136.41 and a 52-week high of $247.04. The company has a 50 day moving average of $169.80 and a 200 day moving average of $196.48. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. The company has a market capitalization of $27.70 billion, a P/E ratio of 20.57, a P/E/G ratio of 1.55 and a beta of 1.18.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, topping the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The company’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. As a group, research analysts forecast that IQVIA Holdings Inc. will post 11.57 EPS for the current fiscal year.

IQVIA announced that its Board of Directors has authorized a stock repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to buy up to 6.8% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s management believes its shares are undervalued.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.